Legend Biotech Corp
NASDAQ:LEGN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.01
69.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Legend Biotech Corp
Wall Street
Price Targets
LEGN Price Targets Summary
Legend Biotech Corp
According to Wall Street analysts, the average 1-year price target for
LEGN
is 84.03 USD
with a low forecast of 60.6 USD and a high forecast of 99.75 USD.
LEGN Last Price Targets
Legend Biotech Corp
The latest public price target was made on Nov 13, 2024 by
Rick Bienkowski
from
Cantor Fitzgerald
,
who expects
LEGN
stock to
rise by 144%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Rick Bienkowski
Cantor Fitzgerald
|
83
USD
Upside 144% |
1 month ago
Nov 13, 2024
|
Legend Biotech Corp. (LEGN) PT Raised to $83 at Cantor Fitzgerald
StreetInsider
|
Gena Wang
Barclays
|
94
USD
Upside 176% |
2 months ago
Oct 15, 2024
|
Barclays Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
StreetInsider
|
|
Justin Zelin
BTIG
|
91
USD
Upside 167% |
2 months ago
Oct 15, 2024
|
BTIG Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
StreetInsider
|
|
Gena Wang
Johnson Rice
|
94
USD
Upside 176% |
2 months ago
Oct 15, 2024
|
Legend Biotech weakness a buying opportunity, says Barclays
TheFly
|
|
Qize Ding
Redburn Partners
|
86
USD
Upside 152% |
2 months ago
Oct 8, 2024
|
Legend Biotech initiated with a Buy at Redburn Atlantic
TheFly
|
Edward Tenthoff
Piper Sandler
|
90
USD
Upside 164% |
6 months ago
Jun 17, 2024
|
Piper Sandler Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
StreetInsider
|
Asthika Goonewardene
Truist Financial
|
88
USD
Upside 158% |
6 months ago
Jun 17, 2024
|
Legend Biotech initiated with a Buy at Truist
TheFly
|
James Shin
Deutsche Bank
|
60
USD
Upside 76% |
7 months ago
May 23, 2024
|
Deutsche Bank Starts Legend Biotech Corp. (LEGN) at Buy
StreetInsider
|
Matthew Harrison
Morgan Stanley
|
82
USD
Upside 141% |
7 months ago
May 17, 2024
|
Legend Biotech Corp. (LEGN) PT Lowered to $82 at Morgan Stanley
StreetInsider
|
Leonid Timashev
RBC Capital
|
86
USD
Upside 152% |
7 months ago
May 14, 2024
|
Legend Biotech price target raised to $86 from $85 at RBC Capital
TheFly
|
George Farmer
Scotiabank
|
65
USD
Upside 91% |
8 months ago
Apr 17, 2024
|
Scotiabank Upgrades Legend Biotech Corp. (LEGN) to Sector Outperform
StreetInsider
|
|
Rick Bienkowski
Cantor Fitzgerald
|
82
USD
Upside 141% |
8 months ago
Apr 3, 2024
|
Cantor Fitzgerald Starts Legend Biotech Corp. (LEGN) at Overweight
StreetInsider
|
Kostas Biliouris
BMO Capital
|
90
USD
Upside 164% |
9 months ago
Mar 14, 2024
|
BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is LEGN's stock price target?
Price Target
84.03
USD
According to Wall Street analysts, the average 1-year price target for
LEGN
is 84.03 USD
with a low forecast of 60.6 USD and a high forecast of 99.75 USD.
What is Legend Biotech Corp's Revenue forecast?
Projected CAGR
67%
For the last 5 years the
compound annual growth rate for
Legend Biotech Corp's revenue is
42%.
The projected
CAGR
for the next 4 years is
67%.
You don't have any saved screeners yet
